sacubitril / valsartan
Neparvis is a heart medicine used in adults with chronic (long-term) heart failure who have symptoms of the disease and reduced ejection fraction (a measure of how well the heart pumps blood). The medicine is also used in adolescents and children from 1 year of age with chronic heart failure who have symptoms of the disease and left ventricular systolic dysfunction (a problem affecting the left side of the heart).
Heart failure is the inability of the heart to pump enough blood around the body.
Neparvis contains the active substances sacubitril and valsartan.
This medicine is the same as Entresto, which is already authorised in the EU. The company that makes Neparvis has agreed that its scientific data can be used for Neparvis (‘informed consent’).
Neparvis : EPAR - Summary for the public (PDF/96.57 KB)
First published: 13/06/2016
Last updated: 22/06/2023
Neparvis : EPAR - Risk-management-plan summary (PDF/86.91 KB)
First published: 07/12/2020
Last updated: 07/09/2023
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Novartis Europharm Limited
|Date of issue of marketing authorisation valid throughout the European Union||
11/09/2023 Neparvis - EMEA/H/C/004343 - IG1654/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Agents acting on the renin-angiotensin system
Paediatric heart failure
Neparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).
Adult heart failure
Neparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).